BioStock: BioInvent is gearing up for clinical data presentations

BioInvent marked a milestone in the third quarter of 2023 with the recruitment of the first patient for the BI-1808 single-agent phase IIa study. BI-1808, a potential novel checkpoint inhibitor, positions BioInvent at the forefront of harnessing the value of TNFR2 in cancer therapy. Meanwhile, the company is preparing for clinical data presentations of BI-1808 at SITC in San Diego, California and of BI-1607 at SABC in San Antonio, Texas.

Read the article at biostock.se:

https://www.biostock.se/en/2023/10/bioinvent-is-gearing-up-for-clinical-data-presentations/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/